{"id":69894,"date":"2026-04-28T04:45:22","date_gmt":"2026-04-28T04:45:22","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/69894\/"},"modified":"2026-04-28T04:45:22","modified_gmt":"2026-04-28T04:45:22","slug":"novo-nordisk-partners-with-openai-in-weight-loss-drug-race","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/69894\/","title":{"rendered":"Novo Nordisk partners with OpenAI in weight loss drug race"},"content":{"rendered":"\n

Novo Nordisk, the maker of popular weight-loss drugs<\/a>\u00a0Ozempic and Wegovy, is partnering with OpenAI to deploy the technology across its operations as it looks to keep pace with\u00a0rapid expansion<\/a>\u00a0in the obesity drug market.<\/p>\n

The Danish company announced in a statement<\/a> on Tuesday that it would use AI to analyze complex datasets, identify promising drug candidates and reduce the time between research and patient application.<\/p>\n

\u201cIt has been structured with strict data protection, governance and human oversight to ensure ethical and compliant use,\u201d the company stated.<\/p>\n

President and CEO Mike Doustdar said the partnership would help discover new treatments for obesity and diabetes and \u201cbringing them to market faster than ever before.\u201d<\/p>\n

\u201cThere are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,\u201d Doustdar said. \u201cIntegrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever.\u201d<\/p>\n

The technology will also allow the company to streamline manufacturing, supply chain and distribution and corporate operations, with AI expected to be fully integrated by the end of the year, according to the announcement.<\/p>\n

Pharmaceutical companies are increasingly turning to artificial intelligence to speed up and simplify clinical development, with experts noting<\/a> its use across a wide range of applications, including the discovery phase, formulation and dosage testing.<\/p>\n

\u201cAI is reshaping industries and in life sciences, it can help people live better, longer lives,\u201d OpenAI CEO Sam Altman said in a statement. \u201cThis collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.\u201d<\/p>\n

Novo Nordisk\u2019s announcement comes just weeks after the Federal Drug Administration (FDA) approved<\/a> a new once-daily weight-loss pill from U.S-based drug manufacturer Eli Lilly.<\/p>\n

Lilly\u2019s Foundayo is the second oral GLP-1 medication to enter the marketplace behind Wegovy, which launched<\/a> in January.<\/p>\n

The FDA\u00a0issued a warning<\/a>\u00a0to Novo Nordisk in early March over its alleged failure to report adverse side effects, including death, in patients who took its weight loss medications.<\/p>\n

Copyright 2026 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.<\/p>\n

For the latest news, weather, sports, and streaming video, head to The Hill. <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk, the maker of popular weight-loss drugs\u00a0Ozempic and Wegovy, is partnering with OpenAI to deploy the technology…\n","protected":false},"author":2,"featured_media":69895,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[3500,2832,272,277],"class_list":{"0":"post-69894","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-data-protection","9":"tag-mike-doustdar","10":"tag-novo-nordisk","11":"tag-weight-loss-drugs"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116480515913496821","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/69894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=69894"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/69894\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/69895"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=69894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=69894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=69894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}